Page 75 - TD-4-1

Tumor Discovery Drug repurposing for pancreatic cancer via AI

generation connectivity map: L1000 platform and the first doi: 10.4143/crt.2022.1600
1,000,000 profiles. Cell. 2017;171(6):1437-1452.e17.
68. Yao J, Huang M, Shen Q, et al. c-Myc-PD-L1 axis sustained
doi: 10.1016/j.cell.2017.10.049 gemcitabine-resistance in pancreatic cancer. Front
Pharmacol. 2022;13:851512.
59. Corsello SM, Nagari RT, Spangler RD, et al. Discovering the
anti-cancer potential of non-oncology drugs by systematic doi: 10.3389/fphar.2022.851512
viability profiling. Nat Cancer. 2020;1(2):235-248.
69. Ebrahimi S, Hosseini M, Shahidsales S, et al. Targeting
doi: 10.1038/s43018-019-0018-6 the Akt/PI3K signaling pathway as a potential therapeutic
strategy for the treatment of pancreatic cancer. Curr Med
60. Xiong G, Wu Z, Yi J, et al. ADMETlab 2.0: An integrated
online platform for accurate and comprehensive Chem. 2017;24(13):1321-1331.
predictions of ADMET properties. Nucleic Acids Res. doi: 10.2174/0929867324666170206142658
2021;49(W1):W5-W14.
70. Konopleva MY, Walter RB, Faderl SH, et al. Preclinical and
doi: 10.1093/nar/gkab255 early clinical evaluation of the oral AKT inhibitor, MK-2206,
for the treatment of acute myelogenous leukemia. Clin
61. Amrutkar M, Gladhaug IP. Pancreatic cancer chemoresistance
to gemcitabine. Cancers (Basel). 2017;9(11):157. Cancer Res. 2014;20(8):2226-2235.
doi: 10.1158/1078-0432.Ccr-13-1978
doi: 10.3390/cancers9110157
71. Simioni C, Martelli AM, Cani A, et al. The AKT
62. Adamska A, Domenichini A, Falasca M. Pancreatic ductal
adenocarcinoma: Current and evolving therapies. Int J Mol inhibitor MK-2206 is cytotoxic in hepatocarcinoma
Sci. 2017;18(7):1338. cells displaying hyperphosphorylated AKT-1 and
synergizes with conventional chemotherapy. Oncotarget.
doi: 10.3390/ijms18071338 2013;4(9):1496-1506.
63. Coppola A, Farolfi T, La Vaccara V, et al. Neoadjuvant doi: 10.18632/oncotarget.1236
treatments for pancreatic ductal adenocarcinoma: Where we
are and where we are going. J Clin Med. 2023;12(11):3677. 72. Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an
allosteric akt inhibitor, enhances antitumor efficacy
doi: 10.3390/jcm12113677 by standard chemotherapeutic agents or molecular
64. Kielb SJ, Shah NL, Rubin MA, Sanda MG. Functional p53 targeted drugs in vitro and in vivo. Mol Cancer Ther.
mutation as a molecular determinant of paclitaxel and 2010;9(7):1956-1967.
gemcitabine susceptibility in human bladder cancer. J Urol. doi: 10.1158/1535-7163.Mct-09-1012
2001;166(2):482-487.
73. Yap TA, Yan L, Patnaik A, et al. First-in-man clinical trial
65. Hill R, Rabb M, Madureira PA, et al. Gemcitabine-mediated of the oral pan-AKT inhibitor MK-2206 in patients with
tumour regression and p53-dependent gene expression: advanced solid tumors. J Clin Oncol. 2011;29(35):4688-4695.
Implications for colon and pancreatic cancer therapy. Cell
Death Dis. 2013;4(9):e791. doi: 10.1200/jco.2011.35.5263
74. Wang Z, Luo G, Qiu Z. Akt inhibitor MK-2206 reduces
doi: 10.1038/cddis.2013.307
pancreatic cancer cell viability and increases the efficacy of
66. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P. gemcitabine. Oncol Lett. 2020;19(3):1999-2004.
Interaction of p53 and DNA-PK in response to nucleoside
analogues: Potential role as a sensor complex for DNA doi: 10.3892/ol.2020.11300
damage. Cancer Res. 2001;61(24):8723-8729. 75. Elnaggar MS, Sminia P, Shehata S, Fedrigo C, Peters G.
1676P - gemcitabine, PI3kinase-Akt pathway inhibition
67. Cao P, Zhang W, Qiu J, Tang Z, Xue X, Feng T. Gemcitabine
inhibits the progression of pancreatic cancer by restraining and radiation in human glioma cell lines. Ann Oncol.
the WTAP/MYC chain in an m6A-dependent manner. 2012;23:ix537.
Cancer Res Treat. 2024;56(1):259-271. doi: 10.1016/S0923-7534(20)34222-8

Volume 4 Issue 1 (2025) 67 doi: 10.36922/td.4709